Kura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $32.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 82.65% from […]

HC Wainwright reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research note released on Tuesday, Benzinga reports. HC Wainwright currently has a $6.00 target price on the biopharmaceutical company’s stock. LXRX has been the subject of several other research reports. Leerink Partners set a $6.00 target price on […]